Obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics files for IPO

Car­mot Ther­a­peu­tics has filed to go pub­lic in a chilly en­vi­ron­ment for new list­ings, but the obe­si­ty biotech’s place in one of drug de­vel­op­ment’s hottest …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.